-
2
-
-
79958043675
-
-
National Cancer Institute. Bethesda, MD
-
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, et al. SEER Cancer Statistics Review, 1975-2012. 2015; National Cancer Institute. Bethesda, MD.
-
(2015)
SEER Cancer Statistics Review, 1975-2012
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
Garshell, J.4
Miller, D.5
Altekruse, S.F.6
Kosary, C.L.7
Yu, M.8
Ruhl, J.9
Tatalovich, Z.10
Mariotto, A.11
Lewis, D.R.12
Chen, H.S.13
-
3
-
-
67650315187
-
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
-
Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27:3109-3116.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3109-3116
-
-
Andre, T.1
Boni, C.2
Navarro, M.3
Tabernero, J.4
Hickish, T.5
Topham, C.6
Bonetti, A.7
Clingan, P.8
Bridgewater, J.9
Rivera, F.10
de Gramont, A.11
-
4
-
-
33646028804
-
Molecular targets of dietary agents for prevention and therapy of cancer
-
Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006; 71:1397-1421.
-
(2006)
Biochem Pharmacol
, vol.71
, pp. 1397-1421
-
-
Aggarwal, B.B.1
Shishodia, S.2
-
5
-
-
53449094405
-
Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent
-
Lopez-Lazaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008; 52 Suppl 1:S103-127.
-
(2008)
Mol Nutr Food Res
, vol.52
, pp. S103-S127
-
-
Lopez-Lazaro, M.1
-
6
-
-
0026615189
-
Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7, 12-dimethylbenz[a]anthracene
-
Huang MT, Wang ZY, Georgiadis CA, Laskin JD, Conney AH. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7, 12-dimethylbenz[a]anthracene. Carcinogenesis. 1992; 13:2183-2186.
-
(1992)
Carcinogenesis
, vol.13
, pp. 2183-2186
-
-
Huang, M.T.1
Wang, Z.Y.2
Georgiadis, C.A.3
Laskin, J.D.4
Conney, A.H.5
-
7
-
-
0028872989
-
Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound
-
Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995; 55:259-266.
-
(1995)
Cancer Res
, vol.55
, pp. 259-266
-
-
Rao, C.V.1
Rivenson, A.2
Simi, B.3
Reddy, B.S.4
-
8
-
-
0036281057
-
Chemopreventive efficacy and pharmacokinetics of curcumin in the min-/+ mouse, a model of familial adenomatous polyposis
-
Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ. Chemopreventive efficacy and pharmacokinetics of curcumin in the min-/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev. 2002; 11:535-540.
-
(2002)
Cancer Epidemiol Biomarkers Prev
, vol.11
, pp. 535-540
-
-
Perkins, S.1
Verschoyle, R.D.2
Hill, K.3
Parveen, I.4
Threadgill, M.D.5
Sharma, R.A.6
Williams, M.L.7
Steward, W.P.8
Gescher, A.J.9
-
9
-
-
6044276740
-
Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance
-
Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004; 10:6847-6854.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 6847-6854
-
-
Sharma, R.A.1
Euden, S.A.2
Platton, S.L.3
Cooke, D.N.4
Shafayat, A.5
Hewitt, H.R.6
Marczylo, T.H.7
Morgan, B.8
Hemingway, D.9
Plummer, S.M.10
Pirmohamed, M.11
Gescher, A.J.12
Steward, W.P.13
-
10
-
-
0035174504
-
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
-
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21:2895-2900.
-
(2001)
Anticancer Res
, vol.21
, pp. 2895-2900
-
-
Cheng, A.L.1
Hsu, C.H.2
Lin, J.K.3
Hsu, M.M.4
Ho, Y.F.5
Shen, T.S.6
Ko, J.Y.7
Lin, J.T.8
Lin, B.R.9
Ming-Shiang, W.10
Yu, H.S.11
Jee, S.H.12
Chen, G.S.13
-
11
-
-
51649118928
-
Phase II trial of curcumin in patients with advanced pancreatic cancer
-
Dhillon N, Aggarwal BB, Newman RA, WolffRA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008; 14:4491-4499.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4491-4499
-
-
Dhillon, N.1
Aggarwal, B.B.2
Newman, R.A.3
Wolff, R.A.4
Kunnumakkara, A.B.5
Abbruzzese, J.L.6
Ng, C.S.7
Badmaev, V.8
Kurzrock, R.9
-
12
-
-
79955804832
-
Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia
-
Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011; 4:354-364.
-
(2011)
Cancer Prev Res (Phila)
, vol.4
, pp. 354-364
-
-
Carroll, R.E.1
Benya, R.V.2
Turgeon, D.K.3
Vareed, S.4
Neuman, M.5
Rodriguez, L.6
Kakarala, M.7
Carpenter, P.M.8
McLaren, C.9
Meyskens, F.L.10
Brenner, D.E.11
-
13
-
-
19344368071
-
Chemopreventive and therapeutic effects of curcumin
-
Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M, Diederich M. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005; 223:181-190.
-
(2005)
Cancer Lett
, vol.223
, pp. 181-190
-
-
Duvoix, A.1
Blasius, R.2
Delhalle, S.3
Schnekenburger, M.4
Morceau, F.5
Henry, E.6
Dicato, M.7
Diederich, M.8
-
14
-
-
25144513892
-
Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells
-
Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res. 2005; 11:6738-6744.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6738-6744
-
-
Lev-Ari, S.1
Strier, L.2
Kazanov, D.3
Madar-Shapiro, L.4
Dvory-Sobol, H.5
Pinchuk, I.6
Marian, B.7
Lichtenberg, D.8
Arber, N.9
-
15
-
-
84869085750
-
Nuclear Factor-κB is expressed in early colon cancer and its down-regulation by Curcumin and Diclofenac is associated with the suppression of proliferation and the induction of apoptosis
-
Rana C, Vaish V, Piplani H, Nehru B, Sanyal SN. Nuclear Factor-κB is expressed in early colon cancer and its down-regulation by Curcumin and Diclofenac is associated with the suppression of proliferation and the induction of apoptosis. Biomedicine & Preventive Nutrition. 2012; 2:228-238.
-
(2012)
Biomedicine & Preventive Nutrition
, vol.2
, pp. 228-238
-
-
Rana, C.1
Vaish, V.2
Piplani, H.3
Nehru, B.4
Sanyal, S.N.5
-
16
-
-
0022587331
-
Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo
-
Mikkelsen B, Pedersen KK, Christiansen LV. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand. 1986; 73:423-427.
-
(1986)
Acta Neurol Scand
, vol.73
, pp. 423-427
-
-
Mikkelsen, B.1
Pedersen, K.K.2
Christiansen, L.V.3
-
17
-
-
0036052028
-
[Effectiveness of tolfenamic acid in the prevention of migraine]
-
Vaitkus A, Pauza V. [Effectiveness of tolfenamic acid in the prevention of migraine]. Medicina (Kaunas). 2002; 38:296-303.
-
(2002)
Medicina (Kaunas)
, vol.38
, pp. 296-303
-
-
Vaitkus, A.1
Pauza, V.2
-
18
-
-
79957691045
-
Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors
-
Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, Holloway RW, Kaja S, Abdelrahim M. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecologic oncology. 2011; 122:163-170.
-
(2011)
Gynecologic oncology
, vol.122
, pp. 163-170
-
-
Basha, R.1
Ingersoll, S.B.2
Sankpal, U.T.3
Ahmad, S.4
Baker, C.H.5
Edwards, J.R.6
Holloway, R.W.7
Kaja, S.8
Abdelrahim, M.9
-
19
-
-
79151475818
-
Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice
-
Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Investigational new drugs. 2011; 29:41-51.
-
(2011)
Investigational new drugs
, vol.29
, pp. 41-51
-
-
Colon, J.1
Basha, M.R.2
Madero-Visbal, R.3
Konduri, S.4
Baker, C.H.5
Herrera, L.J.6
Safe, S.7
Sheikh-Hamad, D.8
Abudayyeh, A.9
Alvarado, B.10
Abdelrahim, M.11
-
20
-
-
84867064767
-
Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer
-
Sankpal UT, Abdelrahim M, Connelly SF, Lee CM, Madero-Visbal R, Colon J, Smith J, Safe S, Maliakal P, Basha R. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. The Prostate. 2012; 72:1648-1658.
-
(2012)
The Prostate
, vol.72
, pp. 1648-1658
-
-
Sankpal, U.T.1
Abdelrahim, M.2
Connelly, S.F.3
Lee, C.M.4
Madero-Visbal, R.5
Colon, J.6
Smith, J.7
Safe, S.8
Maliakal, P.9
Basha, R.10
-
21
-
-
66449110010
-
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression
-
Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Molecular cancer therapeutics. 2009; 8:533-542.
-
(2009)
Molecular cancer therapeutics
, vol.8
, pp. 533-542
-
-
Konduri, S.1
Colon, J.2
Baker, C.H.3
Safe, S.4
Abbruzzese, J.L.5
Abudayyeh, A.6
Basha, M.R.7
Abdelrahim, M.8
-
22
-
-
84885418318
-
Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study
-
Eslin D, Lee C, Sankpal UT, Maliakal P, Sutphin RM, Abraham L, Basha R. Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34:2781-2789.
-
(2013)
Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine
, vol.34
, pp. 2781-2789
-
-
Eslin, D.1
Lee, C.2
Sankpal, U.T.3
Maliakal, P.4
Sutphin, R.M.5
Abraham, L.6
Basha, R.7
-
23
-
-
84876143720
-
Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma
-
Eslin D, Sankpal UT, Lee C, Sutphin RM, Maliakal P, Currier E, Sholler G, Khan M, Basha R. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma. Molecular carcinogenesis. 2013; 52:377-386.
-
(2013)
Molecular carcinogenesis
, vol.52
, pp. 377-386
-
-
Eslin, D.1
Sankpal, U.T.2
Lee, C.3
Sutphin, R.M.4
Maliakal, P.5
Currier, E.6
Sholler, G.7
Khan, M.8
Basha, R.9
-
24
-
-
84902535399
-
Anti-leukemic response of a NSAID, tolfenamic acid
-
Sutphin RM, Connelly SF, Lee CM, Sankpal UT, Eslin D, Khan M, Pius H, Basha R. Anti-leukemic response of a NSAID, tolfenamic acid. Targeted oncology. 2014; 9:135-144.
-
(2014)
Targeted oncology
, vol.9
, pp. 135-144
-
-
Sutphin, R.M.1
Connelly, S.F.2
Lee, C.M.3
Sankpal, U.T.4
Eslin, D.5
Khan, M.6
Pius, H.7
Basha, R.8
-
25
-
-
84982764494
-
Tolfenamic Acid Suppresses Inflammatory Stimuli-Mediated Activation of NF-kappaB Signaling
-
Shao HJ, Lou Z, Jeong JB, Kim KJ, Lee J, Lee SH. Tolfenamic Acid Suppresses Inflammatory Stimuli-Mediated Activation of NF-kappaB Signaling. Biomol Ther (Seoul). 2015; 23:39-44.
-
(2015)
Biomol Ther (Seoul)
, vol.23
, pp. 39-44
-
-
Shao, H.J.1
Lou, Z.2
Jeong, J.B.3
Kim, K.J.4
Lee, J.5
Lee, S.H.6
-
26
-
-
84874290423
-
Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways
-
Shakibaei M, Mobasheri A, Lueders C, Busch F, Shayan P, Goel A. Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways. PLoS One. 2013; 8:e57218.
-
(2013)
PLoS One
, vol.8
-
-
Shakibaei, M.1
Mobasheri, A.2
Lueders, C.3
Busch, F.4
Shayan, P.5
Goel, A.6
-
27
-
-
84884992707
-
Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation
-
Sankpal UT, Lee CM, Connelly SF, Kayaleh O, Eslin D, Sutphin R, Goodison S, Adwan L, Zawia NH, Lichtenberger LM, Basha R. Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2013; 32:675-686.
-
(2013)
Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology
, vol.32
, pp. 675-686
-
-
Sankpal, U.T.1
Lee, C.M.2
Connelly, S.F.3
Kayaleh, O.4
Eslin, D.5
Sutphin, R.6
Goodison, S.7
Adwan, L.8
Zawia, N.H.9
Lichtenberger, L.M.10
Basha, R.11
-
28
-
-
0031460545
-
Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway
-
Hanif R, Qiao L, ShiffSJ, Rigas B. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med. 1997; 130:576-584.
-
(1997)
J Lab Clin Med
, vol.130
, pp. 576-584
-
-
Hanif, R.1
Qiao, L.2
Shiff, S.J.3
Rigas, B.4
-
30
-
-
67349107075
-
Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer
-
Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009; 37:223-230.
-
(2009)
Eur J Pharm Sci
, vol.37
, pp. 223-230
-
-
Shaikh, J.1
Ankola, D.D.2
Beniwal, V.3
Singh, D.4
Kumar, M.N.5
-
31
-
-
2942726181
-
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents
-
Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, Snyder JP, Liotta DC, Shoji M. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem. 2004; 12:3871-3883.
-
(2004)
Bioorg Med Chem
, vol.12
, pp. 3871-3883
-
-
Adams, B.K.1
Ferstl, E.M.2
Davis, M.C.3
Herold, M.4
Kurtkaya, S.5
Camalier, R.F.6
Hollingshead, M.G.7
Kaur, G.8
Sausville, E.A.9
Rickles, F.R.10
Snyder, J.P.11
Liotta, D.C.12
Shoji, M.13
-
32
-
-
79956088980
-
Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells
-
Yunos NM, Beale P, Yu JQ, Huq F. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res. 2011; 31:1131-1140.
-
(2011)
Anticancer Res
, vol.31
, pp. 1131-1140
-
-
Yunos, N.M.1
Beale, P.2
Yu, J.Q.3
Huq, F.4
-
33
-
-
34248573808
-
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products
-
Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 2007; 67:3853-3861.
-
(2007)
Cancer Res
, vol.67
, pp. 3853-3861
-
-
Kunnumakkara, A.B.1
Guha, S.2
Krishnan, S.3
Diagaradjane, P.4
Gelovani, J.5
Aggarwal, B.B.6
-
34
-
-
84903554748
-
Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment
-
Anitha A, Deepa N, Chennazhi KP, Lakshmanan VK, Jayakumar R. Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. Biochim Biophys Acta. 2014; 1840:2730-2743.
-
(2014)
Biochim Biophys Acta
, vol.1840
, pp. 2730-2743
-
-
Anitha, A.1
Deepa, N.2
Chennazhi, K.P.3
Lakshmanan, V.K.4
Jayakumar, R.5
-
36
-
-
77955506109
-
Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation
-
Jutooru I, Chadalapaka G, Lei P, Safe S. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem. 2010; 285:25332-25344.
-
(2010)
J Biol Chem
, vol.285
, pp. 25332-25344
-
-
Jutooru, I.1
Chadalapaka, G.2
Lei, P.3
Safe, S.4
-
37
-
-
84894421263
-
Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors
-
Pathi S, Li X, Safe S. Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors. Molecular carcinogenesis. 2014; 53:E53-61.
-
(2014)
Molecular carcinogenesis
, vol.53
, pp. E53-E61
-
-
Pathi, S.1
Li, X.2
Safe, S.3
-
38
-
-
80052506407
-
Expression of the antiapoptotic protein survivin in colon cancer
-
Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011; 10:188-193.
-
(2011)
Clin Colorectal Cancer
, vol.10
, pp. 188-193
-
-
Hernandez, J.M.1
Farma, J.M.2
Coppola, D.3
Hakam, A.4
Fulp, W.J.5
Chen, D.T.6
Siegel, E.M.7
Yeatman, T.J.8
Shibata, D.9
-
39
-
-
84878648322
-
Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis
-
Krieg A, Werner TA, Verde PE, Stoecklein NH, Knoefel WT. Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis. PLoS One. 2013; 8:e65338.
-
(2013)
PLoS One
, vol.8
-
-
Krieg, A.1
Werner, T.A.2
Verde, P.E.3
Stoecklein, N.H.4
Knoefel, W.T.5
-
40
-
-
37549036729
-
Survivin, cancer networks and pathway-directed drug discovery
-
Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008; 8:61-70.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 61-70
-
-
Altieri, D.C.1
-
41
-
-
33745226982
-
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo
-
Pyrko P, Soriano N, Kardosh A, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen CS, Chen TC, Schonthal AH. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer. 2006; 5:19.
-
(2006)
Mol Cancer
, vol.5
, pp. 19
-
-
Pyrko, P.1
Soriano, N.2
Kardosh, A.3
Liu, Y.T.4
Uddin, J.5
Petasis, N.A.6
Hofman, F.M.7
Chen, C.S.8
Chen, T.C.9
Schonthal, A.H.10
-
42
-
-
33947354209
-
Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells
-
Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, Sasaguri T. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol. 2007; 73:1318-1329.
-
(2007)
Biochem Pharmacol
, vol.73
, pp. 1318-1329
-
-
Sakoguchi-Okada, N.1
Takahashi-Yanaga, F.2
Fukada, K.3
Shiraishi, F.4
Taba, Y.5
Miwa, Y.6
Morimoto, S.7
Iida, M.8
Sasaguri, T.9
-
43
-
-
0033436285
-
Transcriptional analysis of human survivin gene expression
-
Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J. 1999; 344 Pt 2:305-311.
-
(1999)
Biochem J
, vol.344
, pp. 305-311
-
-
Li, F.1
Altieri, D.C.2
-
44
-
-
33947172610
-
Sp1 and Sp3 regulate basal transcription of the survivin gene
-
Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G. Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun. 2007; 356:286-292.
-
(2007)
Biochem Biophys Res Commun
, vol.356
, pp. 286-292
-
-
Xu, R.1
Zhang, P.2
Huang, J.3
Ge, S.4
Lu, J.5
Qian, G.6
-
45
-
-
84870174953
-
Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs
-
Gandhy SU, Kim K, Larsen L, Rosengren RJ, Safe S. Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. BMC Cancer. 2012; 12:564.
-
(2012)
BMC Cancer
, vol.12
, pp. 564
-
-
Gandhy, S.U.1
Kim, K.2
Larsen, L.3
Rosengren, R.J.4
Safe, S.5
-
46
-
-
84886017068
-
Reactive oxygen species mediate tolfenamic acid-induced apoptosis in human colorectal cancer cells
-
Jeong JB, Choi J, Baek SJ, Lee SH. Reactive oxygen species mediate tolfenamic acid-induced apoptosis in human colorectal cancer cells. Arch Biochem Biophys. 2013; 537:168-175.
-
(2013)
Arch Biochem Biophys
, vol.537
, pp. 168-175
-
-
Jeong, J.B.1
Choi, J.2
Baek, S.J.3
Lee, S.H.4
-
47
-
-
34250654084
-
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway
-
Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007; 13:3423-3430.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3423-3430
-
-
Lin, Y.G.1
Kunnumakkara, A.B.2
Nair, A.3
Merritt, W.M.4
Han, L.Y.5
Armaiz-Pena, G.N.6
Kamat, A.A.7
Spannuth, W.A.8
Gershenson, D.M.9
Lutgendorf, S.K.10
Aggarwal, B.B.11
Sood, A.K.12
-
48
-
-
4043111378
-
Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling
-
Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer. 2004; 111:679-692.
-
(2004)
Int J Cancer
, vol.111
, pp. 679-692
-
-
Aggarwal, S.1
Takada, Y.2
Singh, S.3
Myers, J.N.4
Aggarwal, B.B.5
-
49
-
-
0035891055
-
Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines
-
Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 2001; 20:7597-7609.
-
(2001)
Oncogene
, vol.20
, pp. 7597-7609
-
-
Mukhopadhyay, A.1
Bueso-Ramos, C.2
Chatterjee, D.3
Pantazis, P.4
Aggarwal, B.B.5
|